A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Pomalidomide (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms XPORT-MM-031
- 06 Aug 2024 According to a Karyopharm Therapeutics media release, Karyopharm intends to work with the trials sponsor, the European Myeloma Network, to amend certain aspects of the design for this trial, including a reduction in the number of patients that are targeted for enrollment, and the statistical plan. With these updates, Karyopharm expects top-line data readout in 1H 2025; there remains a potential to seek regulatory approval pending the outcome of the study results.
- 26 Sep 2023 According to a Karyopharm Therapeutics media release, The data from this study will be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece.
- 20 Feb 2023 The study protocol amended to included patients with active hepatitis B virus (HBV), a history of hepatitis C virus (HCV), and a history of human immunodeficiency virus (HIV). Patients with any history of central nervous system MM are excluded from this study.